Cite
HARVARD Citation
Huet, S. et al. (n.d.). BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. American journal of hematology. 92 (6), pp. 515-519. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Huet, S. et al. (n.d.). BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. American journal of hematology. 92 (6), pp. 515-519. [Online].